The ESPRIT Trial
The ESPRIT trial will compare the effects of subcutaneous recombinant interleukin-2 (SC rIL-2) and no SC rIL-2 on disease progression and death over a 5 year follow-up period. Patients will be HIV-1 positive with an absolute CD4+ count of above 300/mm3 receiving combination antiretroviral treatment.
CHIP is one of four regional trial centers. The Copenhagen Regional Center is responsible for centers in Denmark, Norway, Sweden, Germany, Spain, Portugal, Belgium, Poland and Austria (875 patients are projected to be enrolled from these countries). ESPRIT is an international collaboration between 23 countries world-wide.
Dr. James Neaton (USA) serves as principal investigator, and the Executive Committee consists of: Dr. Donald Abrams (USA), Dr. David Cooper (Australia), Dr. Janet Darbyshire (UK), Dr. William Duncan (USA), Dr. Sean Emery (Australia), Dr. Clifford Lane (USA) and Dr. Jens D. Lundgren (Denmark).
A five year grant have been awarded by the US National Institutes of Health. The first patient was enrolled in USA on 13 March 2000 and the randomisation was closed with the enrollment of patient no. 4150 on 31 May 2003.
For details about the trial go to the INSIGHT website. For a complete list of INSIGHT publications also see the INSIGHT website.
The EudraCT number for ESPRIT is 2004-000702-46.
For additional information about or help in using the EudraCT number please contact CHIP.
Updated: 18 Jun 2008